DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tafenoquine/Chloroquine DDI Study

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Subjects; Healthy Volunteer

Intervention: Chloroquine, Tafenoquine (Drug); Placebo (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


DDI study of Tafenoquine and Chloroquine

Clinical Details

Official title: Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Primary outcome:

TQ and Chloroquine (Day 2): AUC(0-tau), Cmax and Tmax

CQ and TQ (Day 3): AUC(0-tau), AUC(0-inf), Cmax, Tmax and t1/2

AEs, vital signs, 12-lead ECGs, telemetry, clinical laboratory and ophthalmic assessments

Secondary outcome:

QTcF, QT, QRS, RR and HR as assessed by 12-lead ECG

Changes from baseline in QTcF

Detailed description: Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Healthy as determined by a responsible and experienced physician, based on a medical

evaluation including medical history, physical examination, laboratory tests and ECGs. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the Investigator and GSK medical monitor agree that the abnormality will not introduce additional risk factors and will not interfere with the study procedures.

- Male or female between 18 and 55 years of age inclusive, at the time of signing the

informed consent.

- A female subject is eligible to participate if she is of non-childbearing potential

or of child-bearing potential if has a negative urine pregnancy test at screening and

Day - 1, and agrees to use agreed upon contraception methods until 56 days after

stopping study drug.

- Body weight >=60 kg (132 pounds) and BMI within the range 19-32 kg/m2 (inclusive).

- Capable of giving written informed consent, which includes compliance with the

requirements and restrictions listed in the consent form Exclusion Criteria:

- A positive urine drug/alcohol screen at screening or Day -1.

- History or regular use of tobacco- or nicotine-containing products within 3 months

prior to screening.

- History of illicit drug abuse within 6 months prior to screening.

- History of regular alcohol consumption within 6 months of the study

- Subjects who are unwilling to comply with the lifestyle guidelines required.

- The subject has participated in a clinical trial and has received an investigational

product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary

supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.

- History of sensitivity to any of the study medications or their components.

- Where participation in the study would result in donation of blood or blood products

in excess of 500 mL within a 56 day period.

- Pregnant females as determined by positive urine hCG test at screening or prior to


- Lactating females.

- Subject is mentally or legally incapacitated.

- A positive HIV antibody, Hepatitis B surface antigen or positive Hepatitis C antibody

result within 3 months of screening.

- The subject's systolic blood pressure is outside the range of 90-150mmHg or diastolic

blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects and 45-100bpm for male subjects at screening and Day

- 1.

- Cardiac conduction abnormalities as specified inprotocol

- Any significant arrhythmia which, in the opinion of the principal investigator and

GSK medical monitor, will interfere with the safety for the individual subject.

- History of angina, ischemic heart disease, myocardial infarction, or clinically

significant arrhythmia.

- History of epilepsy, convulsions or psychological disorders.

- History of porphyria.

- AST, ALT or alkaline phosphatase >1. 5 times the upper limit of normal and/or total

bilirubin level outside the normal range at screening. A single repeat is allowed for eligibility determination.

- Documented Glucose-6-phosphate dehydrogenase (G6PD) deficiency, determined by a

quantitative assay of enzyme activity.

- History of hemoglobinopathy; or current or past history of methemoglobinemia or

methemoglobin percentage above the reference range at screening.

- History of previous eye surgery involving the retina, Lasik surgery within 90 days,

or retinal/corneal abnormalities.

- Any clinically significant abnormalities on the screening Humphrey 10-2 visual field


- Best corrected visual acuity worse than 0. 3 logMAR (20/40 Snellen equivalent) (i. e.,

20/40 or better vision will be allowed on study).

Locations and Contacts

GSK Investigational Site, Lenexa, Kansas 66219, United States

GSK Investigational Site, Buffalo, New York 14202, United States

Additional Information

Starting date: March 2009
Last updated: October 15, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017